In today’s article, we will know What Is The Local Treatment Of Asthma
Asthma can be triggered by a variety of factors, including allergens, irritants, and certain infections. It is often treated with medications, such as bronchodilators and corticosteroids, to help open the airways and reduce inflammation. In some cases, lifestyle changes and avoidance of triggers can also help manage the condition.
What is Asthma Disease
The airways of people with asthma become inflamed and narrowed, causing symptoms such as wheezing, coughing, chest tightness, and shortness of breath. These symptoms can be triggered by a variety of factors such as allergens, irritants, physical activity, stress, and certain infections. Asthma can be managed with medications such as bronchodilators, corticosteroids, and anti-inflammatory drugs, as well as lifestyle changes and avoiding known triggers. In severe cases, asthma can lead to hospitalization and can even be life-threatening if not properly managed.
4 Ways to Treatment of Asthma
1. Omalizumab Anti lgE Antibody
Omalizumab is an injectable medication that is used to treat moderate to severe asthma in adults and children who are at least 6 years old. It is a monoclonal antibody that targets the protein immunoglobulin E (IgE), which plays a major role in the development of asthma symptoms. By binding to IgE, omalizumab reduces the amount of IgE in the body, which can help to reduce inflammation and the number of asthma attacks.
Omalizumab is typically used in combination with other asthma medications, such as inhaled corticosteroids and bronchodilators, to improve control of asthma symptoms. It is usually given as a subcutaneous injection once a month and can be used in both allergic and non-allergic asthma.
It’s important to note that Omalizumab is not a substitute for standard asthma therapy and it’s not recommended for the treatment of sudden asthma symptoms. Also, it’s not recommended for people with a history of anaphylaxis or anaphylactoid reactions to recombinant humanized antibodies.
2. Affect Interleukin 5 Pathway
Interleukin (IL) is a family of proteins that play a crucial role in the immune response and inflammation. In asthma, certain types of ILs, such as IL-4, IL-5, and IL-13, are thought to contribute to the chronic inflammation and airway remodeling that characterizes the disease.
Several medications that target the IL pathway have been developed to treat asthma. These include: –
- Monoclonal antibodies that target IL-4 receptor alpha, such as sarilumab, can reduce inflammation and improve lung function.
- Monoclonal antibodies that target IL-5, such as mepolizumab and reslizumab, which can reduce the number of eosinophils (white blood cells) in the lungs and improve asthma control.
- Monoclonal antibodies that target IL-13, such as lebrikizumab and tralokinumab, can reduce inflammation and improve lung function.
These medications are usually used in patients with moderate to severe asthma who are not well controlled with standard therapy. They are usually administered by subcutaneous injection or intravenous infusion.
It’s worth mentioning that these medications are relatively new and are still undergoing clinical trials to fully understand their efficacy and safety profile. They are also relatively expensive and may not be covered by all insurance plans.
3. Mepolizumab
Mepolizumab is a monoclonal antibody that targets the protein interleukin-5 (IL-5) which is involved in the recruitment and activation of eosinophils, a type of white blood cell, in the airways. Eosinophils play a key role in the inflammation that occurs in asthma, particularly in cases where there is an eosinophilic inflammation phenotype. Mepolizumab reduces the number of eosinophils in the lungs, which can help to reduce inflammation and improve asthma control.
Mepolizumab is typically used in adults and children over the age of 12 years with severe eosinophilic asthma, who have been experiencing exacerbations despite using high-dose inhaled corticosteroids and at least one other asthma controller medication, such as a long-acting beta-agonist.
It’s worth mentioning that Mepolizumab is not recommended for the treatment of sudden asthma symptoms (exacerbations) and it’s not a substitute for standard asthma therapy. It’s also important to note that Mepolizumab is not recommended for patients with a history of anaphylaxis or anaphylactoid reactions to recombinant humanized antibodies.
4. Reslizumab
Reslizumab is a monoclonal antibody that targets the protein interleukin-5 (IL-5) which is involved in the recruitment and activation of eosinophils, a type of white blood cell, in the airways. Eosinophils play a key role in the inflammation that occurs in asthma, particularly in cases where there is an eosinophilic inflammation phenotype. Reslizumab reduces the number of eosinophils in the lungs, which can help to reduce inflammation and improve asthma control.
Reslizumab is typically used in adults and children over the age of 12 years with severe eosinophilic asthma, who have been experiencing exacerbations despite using high-dose inhaled corticosteroids and at least one other asthma controller medication, such as a long-acting beta-agonist. It is administered as an intravenous infusion every four weeks.
It’s worth mentioning that Reslizumab is not recommended for the treatment of sudden asthma symptoms (exacerbations) and it’s not a substitute for 5standard asthma therapy. It’s also important to note that Reslizumab is not recommended for patients with a history of anaphylaxis or anaphylactoid reactions to recombinant humanized antibodies.